Product sheet

HT-29 Cells | 300215

General information

Description	The HT-29 cell line, derived from a Grade II human colorectal adenocarcinoma, represents a cornerstone research model in the study of human colon cancers. Derived from a primary tumor in a 44-year-old female in 1964, HT22 cells have been instrumental in advancing our understanding of the adhesion or invasion mechanisms of cancer cells. As a human adenocarcinoma cell line, HT-29 cells exhibit characteristics that closely mimic those of mature intestinal cells, such as enterocytes, underscoring their utility in exploring the dynamics of food digestion and nutrient bioavailability. HT-29 cells are sensitive to conventional colorectal cancer chemotherapies, including 5-fluorouracil and oxaliplatin. This sensitivity, coupled with their ability to express differentiation pathways under specific conditions, such as glucose deprivation or treatment with inducers like butyrate, makes them an invaluable model for investigating the molecular mechanisms underlying cell differentiation and cancer progression. Moreover, HT-29 cells have been utilized as a xenograft tumor model, providing a platform for in vivo studies that mimic the tumor's behavior in the human body. This application allows for the exploration of tumor growth, metastasis, and the efficacy of therapeutic agents in in vivo situations. In summary, the HT-29 cell line is a pivotal tool in medical and biological research, facilitating a deeper understanding of human colon adenocarcinoma, the molecular basis of cancer cell differentiation, and the development of effective cancer treatments.
Organism	Human
Tissue	Colon
Disease	Adenocarcinoma
Synonyms	HT 29, HT29

Characteristics

Age	44 years
Gender	Female
Ethnicity	Caucasian
Morphology	Epithelial-like
Growth properties	Adherent

Product sheet

HT-29 Cells | 300215

Identifiers / Biosafety / Citation

Citation	HT-29 (Cytion catalog number 300215)
Biosafety level	1

Expression / Mutation

Receptors expressed	urokinase receptor(u-PAR), vitamin D (moderate expression), no detectable plasminogen activator activity.
Protein expression	CEA negative, p53 positive
Antigen expression	Blood Type A, Rh+, HLA A1, A3, B12, B17, Cw5, CD4 -, cell surface expression of galactose ceramide (a possible alternative receptor for HIV)
Isoenzymes	Me-2, 1, PGM3, 1-2, PGM1, 1-2, ES-D, 1, AK-1, 1, GLO-1, 1-2, G6PD, B, Phenotype Frequency Product: 0.0230
Oncogenes	myc+, ras+, myb+, fos+, sis+, p53+, abl -, ros -, src –
Tumorigenic	Yes, in nude mice. Forms well differentiated adenocarcinoma consistent with colonic primary (grade I), tumors also form in steroid treated hamsters
Virus susceptibility	human immunodeficiency virus (HIV, LAV)
Products	Secretory component of IgA, carcinoembryonic antigen (CEA), transforming growth factor beta binding protein, mucin, The p53 antigen is overproduced
Karyotype	The stemline chromosome number is hypertriploid with the 2S component occurring at 2.4%. Seventeen marker chromosomes are found in most metaphases, generally in single copy per chromosome. The marker designations are: M1p-(=t(3p-,?) with a deleted short arm), t(7q,?), t(10q,?), i(13q), 19q+a. M6, ?t(8q,9q-), ?xp, M9, 6q+, t(13,?)a, t(13,?)b, 19q+b, M14, M15, 15p+, and xq-. Chromosome 13 is nullisomic and chromosomes 8 and 14 are generally monosomic. No Y chromosome was detected by QM band analysis.

Handling

Culture Medium	EMEM, w: 2 mM L-Glutamine, w: 1.5 g/L NaHCO3, w: EBSS, w: 1 mM Sodium pyruvate, w: NEAA (Cytion article number 820100c)

Medium supplements	Supplement the medium with 10% FBS
Passaging solution	Accutase
Doubling time	24 hours
Subculturing	Remove the old medium from the adherent cells and wash them with PBS that lacks calcium and magnesium. For T25 flasks, use 3-5 ml of PBS, and for T75 flasks, use 5-10 ml. Then, cover the cells completely with Accutase, using 1-2 ml for T25 flasks and 2.5 ml for T75 flasks. Let the cells incubate at room temperature for 8-10 minutes to detach them. After incubation, gently mix the cells with 10 ml of medium to resuspend them, then centrifuge at 300xg for 3 minutes. Discard the supernatant, resuspend the cells in fresh medium, and transfer them into new flasks that already contain fresh medium.
Split ratio	A ratio of 1:3 to 1:8 is recommended
Seeding density	3 x 10^4 cells/cm^2
Fluid renewal	2 to 3 times per week
Freezing recovery	Slow, the cells need roughly 48 hours to settle and adhere.
Freeze medium	CM-1 (Cytion catalog number 800100) or CM-ACF (Cytion catalog number 806100)
Handling of cryopreserved cultures	HT-29 cells are shipped in a deep-frozen state on dry ice. Upon receipt, confirm that the vial remains frozen. For storage, place the cryovial immediately at temperatures below -150 degrees. If you plan to culture the cells immediately, swiftly thaw the vial by shaking it in a 37 degrees water bath with clean water and an antimicrobial agent for 40-60 seconds. Remove the vial once a small ice clump persists, ensuring it remains cold. Proceed with all subsequent steps under aseptic conditions. In a sterile flow hood, disinfect the cryovial with 70% ethanol. Then, gently open the vial and transfer the cell suspension into a 15 ml centrifuge tube pre-filled with 8 ml of room temperature culture medium. Gently mix the cells. For cell separation, centrifuge at 300 x g for 3 minutes and dispose of the supernatant. Skipping centrifugation is optional, although any residual freezing medium should be removed after 24 hours. Resuspend the pellet gently in 10 ml of fresh culture medium and divide between two T25 culture flasks. Follow the subculture protocol for subsequent steps.

Quality control / Genetic profile / HLA

Sterility	Mycoplasma contamination is rigorously excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections.

HT-29 Cells | 300215

STR profile	**Amelogenin**: x,x **CSF1PO**: 11,12 **D13S317**: 11 **D16S539**: 11,12 **D5S818**: 11,12 **D7S820**: 10 **TH01**: 6,9 **TPOX**: 8,9 **vWA**: 17,19 **D3S1358**: 15,17 **D21S11**: 29,30 **D18S51**: 13 **Penta E**: 14,16 **Penta D**: 11,13 **D8S1179**: 10 **FGA**: 20,22
HLA alleles	**A***: 01:01:01, 01.01.1900 00:03 **B***: 01.01.1900 11:01, 01.01.1900 20:03 **C***: 04:01:01 **DRB1***: 04:02:01, 07:01:01 **DQA1***: 02:01:01, 03:01:01 **DQB1***: 02:02:01, 03:02:01 **DPB1***: 04:01 **E**: 01:01, 01:03